Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States.
| Revenue (Most Recent Fiscal Year) | $1.24B |
| Net Income (Most Recent Fiscal Year) | $210.00M |
| PE Ratio (Current Year Earnings Estimate) | 9.91 |
| PE Ratio (Trailing 12 Months) | 12.39 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.00 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 11.20 |
| Pre-Tax Margin (Trailing 12 Months) | 19.29% |
| Net Margin (Trailing 12 Months) | 16.85% |
| Return on Equity (Trailing 12 Months) | -148.76% |
| Return on Assets (Trailing 12 Months) | 23.15% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.71 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.55 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 1.59 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.78 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.82 |
| Earnings per Share (Most Recent Fiscal Year) | $2.50 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.64 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 121.92M |
| Free Float | -- |
| Market Capitalization | $3.71B |
| Average Volume (Last 20 Days) | 3.87M |
| Beta (Past 60 Months) | 0.88 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 60.33% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |